Hoth Therapeutics

Company snapshot

HotHouse Therapeutics is rewriting the future of drug discovery with BotanAI and BotanBio - our AI and plant bioengineering platforms that design and make molecules labs can’t reach. By transforming plants into sustainable biofactories, we unlock vast new chemical space, creating next-generation vaccine adjuvants and breakthrough therapeutics in days, not years. The urgency is clear: 62% of today’

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hoth Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Hoth Therapeutics.

1. Jun 8, 2026 Clinical update

   CLEER-001 — Phase 2

2. May 23, 2026 Clinical update

   HT-001 2% Topical Gel — Phase 2

3. May 23, 2026 Clinical update

   BioLexa- Cohort 1 — Phase 1

4. Nov 19, 2024 Patent grant

   Use of aprepitant for treating Alzheimer's disease

View all clinical trial activity →

• What is Hoth Therapeutics?

  HotHouse Therapeutics is a pharma organization headquartered in Norwich, GB. It trades on NYSE under ticker HOTH. Primary therapeutic focus areas include Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors, Atopic Dermatitis, Acneiform Eruption Due to Chem

• Is Hoth Therapeutics publicly traded?

  Yes. Hoth Therapeutics is listed with ticker HOTH on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Hoth Therapeutics develop or market?

  We link 4 drug profile(s) where Hoth Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hoth-therapeutics#company-drugs.

• What are the latest developments for Hoth Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hoth Therapeutics focus on?

  Hoth Therapeutics focuses on Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors, Atopic Dermatitis, Acneiform Eruption Due to Chemical based on our analysis of their pipeline programs and drug development activities.